Table 3. Clinical, histological and molecular features of RET-rearranged patients.
| N° | Sex / Age | RET diagnosis mm/yy | Last news or death (ς) mm/yy | Smoker (pack-year) | TNM | Stage | Histological subtype / Predominant pattern | FISH-positive rate (%) | FISH pattern | Line of treatment Date mm/yy (nb of cycles) - Cause of therapeutic escape | Best response |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/75 | 02/14 | 01/16 | Former (10) | T1aN0M0 | Ia | ADK / Acinar | 70 | Split | 1. Surgery | Complete response |
| 2 | F/54 | 05/14 | 09/14 (ς) | Never | T4N3M1b | IV | ADK / Solid | 70 | Split | 1. Brain radiotherapy + cisplatine/pemetrexed from 05/14 to 07/14 | Progression of disease |
| 2. Vandetanib from 08/14 to 09/14 | Progression of disease | ||||||||||
| 3 | M/60 | 08/14 | 01/16 (ς) | Current (35) | T4N3M1 | IV | ADK / Papillary | 50 | Split | 1. Cisplatin/pemetrexed/bevacizumab from 08/14 to 10/14 | Partial response |
| 2. Nivolumab from 09/15 to 12/15 | Progression of disease | ||||||||||
| 3. Paclitaxel from 12/15 to 01/16 | Progression of disease | ||||||||||
| 4 | F/94 | 09/14 | 09/15 | Former (30) | T1N0M0 | Ia | ADK / Solid | 50 | Split | Best supportive care | / |
| 5 | F/77 | 10/14 | 12/16 | Never | TxNxM1 | IV | ADK / Acinar | 70 | IGS | 1. Carboplatin/pemetrexed from 08/14 to 11/14 (x4) | Partial response |
| 2. Pemetrexed maintenance from 12/14 to 04/15 | Progression of disease | ||||||||||
| 3. Sunitinib from 05/15 to 07/15 | Progression of disease | ||||||||||
| 4. Paclitaxel from 09/15 to 10/16, then therapeutic break | Stable disease | ||||||||||
| 6 | F/87 | 10/14 | 01/15 (ς) | Former (40) | T4N2M1 | IV | ADK / Solid signet-ring cells | 50 | Split | Best supportive care | / |
| 7 | M/59 | 10/14 | 02/17 | Never | T4N2M1 | IV | NOS | 70 | Split | 1. Cisplatin/pemetrexed/bevacizumab from 8/14 to 10/14 (x4) | Stable disease |
| 2. Pemetrexed maintenance 11/14 - Stop for toxicity, then therapeutic break | Stable disease | ||||||||||
| 3. Erlotinib from 08/15 to 02/16 | Progression of disease | ||||||||||
| 4. Nivolumab from 03/16 to 06/16 | Progresion of disease | ||||||||||
| 5. Vandetanib from 12/16 - ongoing | Stable disease | ||||||||||
| 8 | F/75 | 04/15 | 03/16 | Never | T2N0M0 | Ib | ADK / Cytology | 80 | Split | 1. Surgery | Complete response |
| 9 | M/50 | 05/15 | 02/17 (ς) | Current (20) | T1N3M1 | IV | ADK / Solid | 80 | Split | 1. Cisplatin/pemetrexed from 08/13 to 10/13 (x4) | Partial response |
| 2. Pemetrexed maintenance from 11/13 to 08/14, then therapeutic break | Stable disease | ||||||||||
| 3. Pemetrexed at bone progression from 09/15 to 03/16 - Stop for toxicity | Stable disease | ||||||||||
| 4. Nivolumab from 10/16 to 01/17 | Progression of disease | ||||||||||
| 10 | F/44 | 06/15 | 04/16 (ς) | Never | T1N3M1b | IV | ADK / Solid | 50 | Split | 1. Cisplatin/pemetrexed/bevacizumab from 06/15 to 09/15 | Partial response |
| 2. Paclitaxel from 10/15 to 03/16 | Partial response | ||||||||||
| 11 | F/83 | 06/15 | 06/15 (ς) | Never | T3N3M1 | IV | ADK / Solid | 60 | Split | 1. Gefitinib from 28/05/15 to death (3 days) | Progression of disease |
| 12 | F/88 | 07/15 | 07/15 (ς) | NA | M1a | IV | ADK / Undetermined | 50 | Split | 1. Gefitinib from 06/15 to death | Progression of disease |
| 13 | M/63 | 11/15 | 12/15 | Current (40) | T2N0M0 | Ib | ADK / Solid | 50 | IGS | 1. Surgery | Complete response |
| 14 | M/57 | 12/15 | 01/17 (ς) | Current (70) | T4N3M1 | IV | ADK / Acinar | 60 | IGS | 1. Cisplatin/docetaxel from 06/14 to 08/14 (x4) | Partial response |
| 2. Pemetrexed from 09/14 to 06/15 - Stop for toxicity | Stable disease | ||||||||||
| 3. Nivolumab from 11/15 to 12/15 | Progression of disease | ||||||||||
| 4. Docetaxel from 01/16 to 05/16, then therapeutic break - Brain metastases | Partial response | ||||||||||
| 5. Erlotinib 08/16 | Progression of disease | ||||||||||
| 6. Sunitinib 11/16 | Progression of disease | ||||||||||
| 15 | M/68 | 12/15 | 12/15 (ς) | Former (5) | M1 | IV | ADK / Solid signet-ring cells | 60 | Split | 1. Cisplatin/pemetrexed 12/15 (x1) | Progression of disease |
| 16 | F/80 | 01/16 | 03/17 | Never | T2N2M1 | IV | ADK / Solid signet-ring cells | 90 | Split | 1. Carboplatin/paclitaxel from 06/16 to 05/16 (x6) | Stable disease |
| 2. Paclitaxel maintenance (x9) - Stop for toxicity 11/16 | Stable disease | ||||||||||
| 3. Vandetanib from 12/16 - ongoing | Stable disease | ||||||||||
| 17 | M/61 | 04/16 | 12/16 | Current (60) | T4N2M0 | IIIb | ADK / Acinar | 80 | IGS | 1. Radiotherapy + carboplatin/paclitaxel from 03/16 to 05/16 | Progression of disease |
| 2. Pemetrexed from 09/16 to 12/16 (x5) | Stable disease | ||||||||||
| 18 | F/43 | 06/16 | 07/16 | Former (10) | T1aN0 | Ia | ADK / Lepidic | 90 | Split | 1. Surgery | Complete response |
M: Male; F: Female; NOS: not otherwise specified; Split: Split signals; IGS: Isolated 3′ Green Signal; NA: Not Available